This study is a multicenter, prospective, observational study aimed at investigating the efficacy and safety of triple targeted drug therapy in patients with arterial pulmonary hypertension (PAH) who are not at low risk and are receiving initial treatment. The prognosis of arterial pulmonary hypertension is explored.

Inclusion Criteria:

• Consent and sign the informed consent form
• Non-low-risk PAH treatment-naive patients

Exclusion Criteria:

• Positive acute vascular response test for idiopathic/hereditary/drug-related arterial pulmonary hypertension
• Pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis (PVOD/PCH) with arterial pulmonary
• Pregnant or lactating women
• Suffering from mental illness or cognitive impairment
• PAH patients with concurrent malignant tumors
• Patients with moderate to severe hepatic impairment, renal impairment, and severe anemia
• Currently participating in other interventional clinical studies
• Key clinical data is incomplete, or the investigator considers that the patient has other factors that make them unsuitable for this study.

Adult patients with arterial pulmonary hypertension